11 High Growth Healthcare Stocks to Buy Now
On March 26, Stephanie Link, Hightower chief investment strategist, appeared on CNBC's ‘Squawk Box’ to talk about the latest market trends, where investors can find opportunities, and the effects ...
Apellis Pharmaceuticals Inc. (APLS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 12,222,222 | $307,022,217 | 3.02% | |
| 2. | Deep Track Capital David Kroin | 7,750,000 | $194,680,000 | -4% | 3.47% |
| 3. | Suvretta Capital Management Aaron Cowen | 4,139,426 | $103,982,381 | +44% | 2.13% |
| 4. | Polar Capital Brian Ashford-Russell And Tim Woolley | 3,706,510 | $93,107,531 | +40% | 0.36% |
| 5. | Siren L.L.C. Raymond Debbane | 2,578,396 | $64,769,308 | 1.93% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 250,000 | $10,000,000.00 | 12,806,342 | 2021-11-18 | Filing | |
| $31.81 | 5,000 | $159,034.00 | 5,000 | 2020-05-08 | Filing | |
| $37.00 | 540,540 | $19,999,980.00 | 12,556,342 | 2020-01-13 | Filing | |
| $29.71 | 11,699 | $347,629.94 | 11,699 | 2019-08-29 | Filing | |
| $17.00 | 441,176 | $7,499,992.00 | 12,015,802 | 2019-03-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.15 | 368 | $8,152.56 | 114,591 | 2026-02-11 | Filing | |
| $21.77 | 2,797 | $60,877.82 | 86,527 | 2026-01-22 | Filing | |
| $21.77 | 2,064 | $44,923.79 | 49,805 | 2026-01-22 | Filing | |
| $21.77 | 3,371 | $73,371.16 | 78,353 | 2026-01-22 | Filing | |
| $21.77 | 5,928 | $129,025.29 | 1,151,382 | 2026-01-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,721,352 | $319,560,362 | 0.06% | |
| 2. | 10,674,865 | $268,152,609 | 0% | |
| 3. | 9,173,004 | $230,425,882 | 0.01% | |
| 4. | 7,666,764 | $192,589,112 | 1.93% | |
| 5. | 6,260,113 | $157,254,037 | 0% |
News See All
Here is Why JPMorgan is Overweight on Apellis Pharma (APLS)
On March 5, Anupam Rama from JPMorgan increased the price target on Apellis Pharmaceuticals Inc. (NASDAQ:APLS) from $36 to $37.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2025 Earnings Call Transcript February 24, 2026Apellis Pharmaceuticals, Inc. misses on earnings expectations.
BofA Upgrades Apellis (APLS) to Buy Citing Rapid Empaveli Adoption and Underappreciated Kidney Disease Market Potential
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the best high short interest stocks with biggest upside potential.
11 Best High Short Interest Stocks With Biggest Upside Potential
On January 27, Sherry Paul, a senior portfolio manager at Morgan Stanley, appeared on CNBC's 'Closing Bell' to discuss whether more volatility is ahead, following a volatile week in the market.
Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the best upside stocks to buy now.
12 Best Upside Stocks to Buy Now
On November 14, Alli McCartney, UBS Private Wealth Management managing director, joined 'Squawk Box' on CNBC to discuss the latest market trends and what to make of the recent volatility.
Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) ranks among the most oversold biotech stocks to invest in. On November 3, Mizuho maintained its Neutral rating for Apellis Pharmaceuticals Inc.
9 Oversold Biotech Stocks to Invest In
Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value and healthcare.
Hedge Fund Resource Center